Clinical trial
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical…
NCT00215202 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00215202 |
|---|---|
| Title | Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) |
| Official title | A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | AstraZeneca Industry M.D. Anderson Cancer Center Dana-Farber Cancer Institute Kentuckiana Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Nonresectable Adrenocortical Carcinoma |
| Intervention type | Drug |
| Interventions | Iressa (ZD1839) |
| Enrollment | 16 |
| Start date | Aug 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | May 17, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: